RBC Capital lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $415 from $423 and keeps a Sector Perform rating on the shares. Compared to Q2, the company registered a more uneventful quarter, the analyst tells investors in a research note. Vertex’s cystic fibrosis, CF, franchise remains healthy, though slow launches elsewhere and increased spend underscore intrinsic limitations to operating leverage growth as the company diversifies, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Optimistic Outlook for Vertex Pharmaceuticals Driven by Strong CF Business and Promising Pipeline Developments
- Vertex Pharmaceuticals price target lowered to $445 from $455 at Stifel
- Vertex Pharmaceuticals: Strong Buy Rating Amid Promising Growth and Strategic Expansion
- Vertex Pharmaceuticals: Hold Rating Maintained Amid Mixed Financial Signals
- Vertex Pharmaceuticals price target raised to $414 from $408 at Barclays